This is a routine 10b5-1 plan sale by an officer, not a new discretionary decision. Traders should not interpret this as negative sentiment, but rather as part of a pre-established exit strategy. Monitor for completion of the sale via Form 4 filings.
Price Chart
Executive Summary
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to report the proposed sale of 14,640 shares, following a series of recent 10b5-1 plan sales totaling over $12.1M in the past month. This filing is part of an ongoing, pre-arranged selling plan and not an isolated event.
Key Facts
- Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose the sale of 14,640 common shares.
- The sale is part of a 10b5-1 trading plan, with recent sales already executed: 7,600 shares (~$649K) on 03/31/2026, 24,727 shares (~$1.98M) on 03/25/2026, 91,250 shares (~$7.06M) on 03/23/2026, and others totaling over $12.1M in the past month.
- The proposed sale proceeds will be received in cash and are not tied to any new insider decision, as 10b5-1 plans are pre-scheduled.
- Recent insider activity shows 4 sell transactions in the last 30 days totaling $3.8M, consistent with this pattern.
Financial Impact
Approximately $1.22M based on 14,640 shares at ~$83.29/share (implied from prior sales), a small fraction of Kymera's $6.8B market cap.
Risk Factors
- Perception risk: Large cumulative insider sales may be viewed negatively by the market despite being pre-planned.
- Execution risk: If future sales under this plan accelerate or expand, it could increase selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003151 |
| Document: 0001950047-26-003151-index.html | 0001950047-26-003151 |
| Document: 0001950047-26-003151.txt | 0001950047-26-003151 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 14w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access